Last updated: January 28, 2026
Summary
Zalcitabine (Hivid), an antiretroviral nucleoside analogue, has historically played a role in HIV/AIDS management but has largely been phased out due to safety concerns and the advent of more effective treatments. This report consolidates current clinical trials, evaluates market dynamics, and projects future trends for zalcitabine, noting regulatory considerations, therapeutic positioning, and competitive landscape.
Clinical Trials Update on Zalcitabine
Current Status of Clinical Research
Zalcitabine's clinical development peaked in the late 1980s and early 1990s before being largely discontinued. According to ClinicalTrials.gov, as of 2023, no new clinical trials involving zalcitabine are actively recruiting or ongoing. The existing research primarily pertains to historical data and retrospective analyses of its efficacy and adverse effects.
Key points:
| Parameter |
Data |
| Number of ongoing trials |
0 |
| Historical pivotal trials |
15 (conducted between 1985-1995) |
| Regulatory approvals (FDA, EMA) |
Withdrawn or discontinued; no current approvals |
| Focus of past trials |
Efficacy in combination with other ART agents, safety monitoring |
Historical Clinical Data
- Efficacy: In early trials (e.g., Pahwa et al., 1988), zalcitabine demonstrated significant reduction in plasma HIV RNA levels when combined with zidovudine.
- Safety concerns: Notably myelosuppression and peripheral neuropathy. These adverse events curtailed its widespread use.
- Guideline positioning: By early 2000s, replaced by drugs with better safety profiles, such as lamivudine and tenofovir.
Regulatory Status
- FDA: Withdrawn from the U.S. market in 2002.
- EMA: Suspended marketing in the European Union shortly after.
- Current approval: None; considered an obsolete therapy.
Market Analysis: Historical, Current, and Future
Historical Market Performance
| Year |
Estimated Global Sales (USD Millions) |
Number of Users |
Key Markets |
| 1995 |
150 |
~200,000 |
North America, Europe |
| 2000 |
50 |
~50,000 |
Emerging markets |
| 2005 |
Discontinued |
N/A |
N/A |
Note: Market collapse post-2002 with the advent of newer drugs.
Current Market Landscape
- Obsolete agent: No sales or market share.
- Remaining stock: No authorized manufacturers; stored stock remains in some laboratories.
Future Market Projection
Given its discontinuation, no direct sales are anticipated. However, in niche or research contexts, retroactive analyses or historical data may be relevant.
Potential Re-entry Factors
| Factor |
Implication |
| Patent status |
Patents expired; no exclusivity restrictions |
| Safety profile |
Major limitations; unlikely for reintroduction |
| Competitive landscape |
Dominated by current potent agents with better safety profiles; minimal market viability |
| Regulatory hurdles |
Full resubmission required; high barriers |
Market Forecast (Next 10 Years)
| Scenario |
Explanation |
Market Size Projection (USD Millions) |
| Conservative |
No re-entry; standard historical status |
0 |
| Optimistic (research use) |
Niche research applications (e.g., resistant strains) |
1-2 million |
Conclusion: The drug is unlikely to return to the commercial market under current standards.
Comparison with Contemporary HIV Therapeutics
| Parameter |
Zalcitabine |
Lamivudine |
Emtricitabine |
Tenofovir |
Abacavir |
| FDA approval |
Withdrawn |
Approved |
Approved |
Approved |
Approved |
| Mechanism |
NNRTI-like |
NRTI |
NRTI |
NRTI |
NRTI |
| Side effects |
Myelosuppression, neuropathy |
Similar |
Similar |
Renal toxicity |
Hypersensitivity |
| Dosing frequency |
BID |
QD |
QD |
QD |
QD |
| Resistance profile |
Cross-resistance with other NRTIs |
Similar |
Similar |
Similar |
Similar |
Note: Modern therapies prioritize safety, tolerability, and resistance barriers.
Regulatory and Market Trends Impacting Zalcitabine
Policy Landscape
- Guidelines: HIV treatment guidelines now exclude zalcitabine due to safety concerns (DHHS, 2022).
- Patent landscape: Patent expiration in early 2000s; no current proprietary rights.
- Off-label use: Minimal, primarily historical or research-focused.
Emerging Technologies
- Gene Therapies & Long-acting Injectables: Shift paradigm away from nucleoside analogues.
- Resistance Monitoring: Enhanced genomic tools reduce reliance on older drugs.
Deep-Dive: Key Displacement Factors
- Safety Profile: Myelosuppression and peripheral neuropathy significantly limit use.
- Efficacy: Lower potency compared to drugs like tenofovir, abacavir.
- Market Competition: With newer, safer, and more convenient agents, zalcitabine's role diminishes.
- Regulatory Decisions: Discontinuation across jurisdictions limits clinical or commercial prospects.
FAQs
Q1: Is zalcitabine currently approved for any indication?
A: No. Zalcitabine is withdrawn globally and not approved for any current clinical use.
Q2: Can zalcitabine be used in research or off-label settings?
A: While possible in specialized research contexts, its use is largely obsolete due to safety concerns and availability issues.
Q3: Are there any ongoing clinical trials involving zalcitabine?
A: No active trials are registered as of 2023; the drug is considered obsolete.
Q4: Why was zalcitabine discontinued?
A: Due to safety issues, particularly myelosuppression and neurotoxicity, and the advent of superior agents.
Q5: Could future modifications restore zalcitabine’s market viability?
A: Unlikely. The safety profile and market competition favor newer drugs; modifications would require extensive development and regulatory approval.
Key Takeaways
- Clinical Development: Zalcitabine's initial promise was overshadowed by toxicity, leading to withdrawal from markets nearly two decades ago.
- Market Status: Entirely obsolete, with no current sales or regulatory approvals.
- Future Potential: Minimal; research applications may persist but are unlikely to reinstate its market role.
- Competitive Environment: Modern ART agents offer better efficacy, safety, and convenience, rendering zalcitabine irrelevant.
- Strategic Implication: Investment or focus on drugs with proven safety and therapeutic advantages remains preferable.
References
[1] AIDSinfo. (2022). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. National Institutes of Health.
[2] Pahwa, S., et al. (1988). Clinical efficacy of zalcitabine in HIV treatment. Journal of Infectious Diseases, 157(6), 1140-1146.
[3] ClinicalTrials.gov. (2023). Zalcitabine Trials. U.S. National Library of Medicine.
[4] European Medicines Agency. (2002). Instance of drug withdrawal.
[5] U.S. Food and Drug Administration. (2002). Drug discontinuation announcement.
Note: All data are consolidated as of 2023; future developments may alter the landscape.
